Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. - Wikidata - awgldk - TriplyDB

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.

http://www.wikidata.org/entity/Q45230546

about

Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer.Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute Bi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status.Chemotherapy for advanced gastric cancer: across the years for a standard of care.Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.The role of taxanes in the management of gastroesphageal cancer Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.The emerging role of oxaliplatin in the treatment of gastric cancer.Recent developments in the systemic therapy of advanced gastroesophageal malignancies.Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel.Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.Docetaxel in the treatment of gastric cancer.Capecitabine in advanced gastric cancer.Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer.Systemic therapy for advanced gastric cancer: a clinical practice guideline.Metastatic gastric cancer treatment: a little slow but worthy progress.Chemotherapy for advanced gastric cancer.The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials Role of taxanes in pancreatic cancer.Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression.Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial.Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial.Retrospective evaluation of the efficacy of first-line treatment of advanced gastric cancer with docetaxel and oxaliplatin.

P2860

Q24810562-E067CD3E-B363-415D-A3CF-607EA9CA68B8 Q26798400-051FC01A-3997-4812-B1FE-8621B08A1C99 Q33576276-AEBF94D8-2AFF-4810-810A-EE386593FD40 Q33658659-5903E75A-12C6-4AC0-95BA-05F90D00D7A9 Q34254234-42B0E8FE-E1D3-4E06-ADA7-9AD86BFC03D5 Q34447512-57E51150-EA21-449E-86DB-B9792FC721D0 Q34617795-D482F4AE-2068-4217-AA46-14EB94644608 Q34852173-78E46328-B157-41FF-85AB-0F2D16B1E65B Q35208094-56770491-F0AD-4ABC-9A02-C6445FAFF056 Q36097240-C8FAA267-D76E-4888-80AC-F2E27A7A718D Q36117215-EA875A80-A0D4-4EC9-80F0-B3A925BFA342 Q36376345-A32DE761-EA78-4CCE-9B87-6233D8979AA1 Q36376439-03911CA3-E9D0-4E78-BAB2-B43221CC2CE1 Q36402491-48310C3D-AD93-4B5E-B2BE-CA70C3269795 Q36548725-F8599026-7675-4323-A161-7547A1F32997 Q36610215-26DBD8A3-8F58-4922-A6AD-164CA0068D81 Q36611262-B2FDF130-5BA4-4ED2-87AB-8C491530BAAC Q36614036-ECD7F9A8-1238-46D4-A01F-16325176E381 Q36614394-1EF09DE6-674F-43F7-AB2D-74136A595C7F Q36616503-85FE5A25-81C2-47A8-9D2D-E11874FC01F0 Q36979346-7C7E6C3F-74CB-4E6C-8219-06D045014AB3 Q37197679-BD0F4CA8-3DF1-46DE-9CEA-005D97050BEE Q37236380-0A284AE2-32EC-4F17-B0F8-7A5220D3939B Q37923311-DBE975F0-AD08-46DD-BC36-D255271E0650 Q38075499-118832C6-98D2-4FAE-9887-A85CBBE3C461 Q38604012-986599D2-FF28-46F5-8FBB-752DB0F9F83B Q38941416-DFF0A5E2-B0F1-473D-82F9-1CB4E2E133E1 Q39778923-F8D941B2-DB13-4CA8-9F7A-06C2F07B0E9D Q41044387-28C302EC-16B8-4D8A-98FC-37B955276882 Q41187621-E630E26D-FC72-4862-A906-311DE198B3C4 Q42181610-09C80B0A-8FDD-47AC-88E3-657D5D9B8927 Q42323567-1C86E5F0-AAD5-4C2E-9770-F8B5E637F183 Q44734913-A94370CE-90F6-4B00-9273-3FA10E18CA53 Q45001390-D2D91EFA-A563-4B5B-97EC-2E17CF75E07F Q46321335-7953FA2A-EEED-4CC3-A5AF-223CE9DE7F04 Q47402625-CD23FC8E-9D9C-41F1-A30F-1374AF711AF7 Q48052472-11FD1901-9A8C-4698-A103-B6E095EAB401 Q53665182-05502361-EA07-4397-84C1-E4E744D7EB6D

P2860

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.

http://www.wikidata.org/entity/Q45230546

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Docetaxel and continuous-infus ...... : a randomized phase II study.

@en

Docetaxel and continuous-infus ...... : a randomized phase II study.

@nl

type

label

Docetaxel and continuous-infus ...... : a randomized phase II study.

@en

Docetaxel and continuous-infus ...... : a randomized phase II study.

@nl

prefLabel

Docetaxel and continuous-infus ...... : a randomized phase II study.

@en

Docetaxel and continuous-infus ...... : a randomized phase II study.

@nl

P1433

Q45230546-EB99C66B-C388-45BF-84DF-18D0564FA8AF

P1476

Q45230546-999FEEE7-F85E-43A0-9D41-F80C36ABAD5F

P2093

Q45230546-097BCF17-99FA-481E-BCB1-FE0BF4F6F868

Q45230546-0B7795A8-5258-4C92-9729-C287C187BD1A

Q45230546-3784D583-5C8C-469C-AD8C-05AB0725C8D1

Q45230546-37935D42-C9DC-4019-8B6C-1A0FCE6D1964

Q45230546-883A19F1-09E9-4F83-AE11-E63D41705975

Q45230546-93EF1EF2-C7B3-44CA-9B3E-475CC0B80B89

Q45230546-A8AB633F-0405-4D13-9EAE-4B9DDAF5B485

Q45230546-ABA95264-180C-46B4-8906-2A2A882E7290

Q45230546-AD6540F6-16EE-41B7-B4CD-80D44BB6B2D0

Q45230546-F134C09F-E44B-469F-983E-0B81AF59800D

P304

Q45230546-34C2A4B2-9AC2-4946-99F7-FD04FB44B784

P31

Q45230546-3D1D8BEA-1E6E-4455-9E0E-CEB1428EF66A

P356

Q45230546-1A20E708-B95F-448A-8B41-A243640ACFF2

P407

Q45230546-01728591-CABB-494C-9AE6-56932C0272D5

P433

Q45230546-DFA2114D-D9C6-467C-A5AB-4102F76A36EF

P478

Q45230546-86AAD8DE-5FA2-4E93-8DCF-2158BD7F8225

P577

Q45230546-0DCEFA60-CEF0-47BD-88B3-09EB60FDB327

P698

Q45230546-1B2C1473-81A5-4E38-9C13-0AA7EA3B6E19

P921

Q45230546-E2A43EBE-6E31-44F9-91A5-CBEE009A059F

P356

JCO.2005.02.163

P1433

Journal of Clinical Oncology

P1476

Docetaxel and continuous-infus ...... : a randomized phase II study.

@en

P2093

Albrecht Kretzschmar

http://www.w3.org/2001/XMLSchema#string

Bernd Dörken

http://www.w3.org/2001/XMLSchema#string

Christian Scholz

http://www.w3.org/2001/XMLSchema#string

Daniel Pink

http://www.w3.org/2001/XMLSchema#string

Dirk Hennesser

http://www.w3.org/2001/XMLSchema#string

Dorothea Kingreen

http://www.w3.org/2001/XMLSchema#string

Michael Repp

http://www.w3.org/2001/XMLSchema#string

Peter C Thuss-Patience

http://www.w3.org/2001/XMLSchema#string

Peter Reichardt

http://www.w3.org/2001/XMLSchema#string

Simone Micheel

http://www.w3.org/2001/XMLSchema#string

P304

494-501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.02.163

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15659494

http://www.w3.org/2001/XMLSchema#string

P921